Unlike mGluR1, mGluR5 expression is rich in the cerebrum (Varnas et al., 2018), and a larger number of studies have investigated the role of mGluR5 in AD-related cognitive dysfunction, suggesting that it is a promising target for AD treatment (Caraci et al., 2018). This evidence concerns the gene GRM1 and Alzheimer disease.